Matthew L. Posard
Matthew L. Posard's purchase track record
Matthew L. Posard has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 11/30/2021 | NAUT | $226K | -19.4% | -24.5% | -9.5% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
Roth Capital initiates coverage on NAUT with $3.50 target. Roth Capital began tracking Nautilus Biotechnology with a Buy rating and a price target of $3.50. This new analyst note adds to the current consensus, where the average target from two analysts is $4.00. The stock is currently trading within its 52-week range of $0.72 to $4.31.
Transaction History
| HALO | ▼ Sell | Open Market | 730 | $78K | 10/1/2026 | View on chart |
| HALO | ▼ Sell | Open Market | 3,300 | $358K | 10/1/2026 | View on chart |
| HALO | ▼ Sell | Open Market | 1,100 | $121K | 10/1/2026 | View on chart |
| HALO | ▼ Sell | Open Market | 100 | $11K | 10/1/2026 | View on chart |
| HALO | ▼ Sell | Open Market | 3,100 | $329K | 9/16/2026 | View on chart |
| HALO | ▼ Sell | Open Market | 3,000 | $320K | 9/16/2026 | View on chart |
| HALO | ▼ Sell | Open Market | 8,896 | $961K | 9/16/2026 | View on chart |
| HALO | ▼ Sell | Open Market | 4,000 | $436K | 9/16/2026 | View on chart |
| HALO | ▲ Buy | Grant | 3,796 | $0 | 5/5/2026 | View on chart |
| HALO | ▲ Buy | Grant | 4,165 | $0 | 5/1/2025 | View on chart |
| HALO | ▼ Sell | Open Market | 9,881 | $570K | 8/14/2024 | View on chart |
| HALO | ▼ Sell | Open Market | 10,000 | $562K | 8/13/2024 | View on chart |
| HALO | ▼ Sell | Open Market | 10,000 | $557K | 8/12/2024 | View on chart |
| HALO | ▼ Sell | Open Market | 10,000 | $506K | 6/12/2024 | View on chart |
| HALO | ▼ Sell | Open Market | 10,000 | $500K | 6/11/2024 | View on chart |
| HALO | ▲ Buy | Grant | 6,501 | $0 | 4/25/2024 | View on chart |
| HALO | ▲ Buy | Grant | 8,065 | $0 | 5/5/2023 | View on chart |
| HALO | ▼ Sell | Open Market | 10,000 | $561K | 12/6/2022 | View on chart |
| HALO | ▼ Sell | Open Market | 10,000 | $557K | 12/5/2022 | View on chart |
| HALO | ▼ Sell | Open Market | 10,000 | $588K | 12/2/2022 | View on chart |
| HALO | ▲ Buy | Grant | 6,206 | $0 | 5/5/2022 | View on chart |
| NAUT | ▲ Buy | Open Market | 10,000 | $45K | 12/1/2021 | View on chart |
| NAUT | ▲ Buy | Open Market | 10,000 | $45K | 12/1/2021 | View on chart |
| NAUT | ▲ Buy | Open Market | 10,000 | $44K | 12/1/2021 | View on chart |
| NAUT | ▲ Buy | Open Market | 20,000 | $91K | 11/30/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 5, 2026
Halozyme Adds Jim Daly to Board Amid Q2 Earnings Review
Halozyme Therapeutics has appointed Jim Daly to its Board of Directors, a move that signals continued focus on governance and long-term strategy. This update arrives alongside a broader market review of the company's Q2 performance relative to other therapeutics firms. The stock is currently trading above its average analyst target price, with recent technical data showing confirmation near key support levels.
Halozyme Adds Jim Daly to Board Amid Q2 Earnings Review. Halozyme Therapeutics has appointed Jim Daly to its Board of Directors, a move that signals continued focus on governance and long-term strategy. This update arrives alongside a broader market review of the company's Q2 performance relative to other therapeutics firms. The stock is currently trading above its average analyst target price, with recent technical data showing confirmation near key support levels.